Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies
Sign Up to like & getrecommendations! Published in 2023 at "Life"
DOI: 10.3390/life13061272
Abstract: Concurrent infections in hematological malignancies (HM) are major contributors to adverse clinical outcomes, including prolonged hospitalization and reduced life expectancy. Individuals diagnosed with HM are particularly susceptible to infectious pathogens due to immunosuppression, which can… read more here.
Keywords: targeted therapies; infectious complications; secondary use; infections secondary ... See more keywords